Severe Asthma Web-based Database | Severe Asthma Toolkit

The Australasian Severe Asthma Registry (ASAR) is a multicentre Clinical Quality Registry (CQR) of individuals with confirmed severe refractory asthma and non-severe controlled asthma in Australia and New Zealand.

ASAR (formerly the Severe Asthma Web-based Database ‘SAWD’) was established by the Australasian Severe Asthma Network (ASAN) in 2013. It is under the management of the ASAN Steering Committee and governance of the Thoracic Society of Australia and New Zealand (TSANZ). There are more than 20 sites contributing data to ASAR.

The registry encompasses a multicentre cross-sectional study of the characteristics of severe asthma, based around asthma phenotypes, and a prospective cohort study of the outcomes and future risks of phenotypes of severe asthma. The ASAR platform comprises a consistent and well characterised patient population. The ASAR platform is flexible and enables the implementation of new research modules as the need arises. ASAR also serves as a Databank for future approved research studies.

The ASAR:

Collects and reports on data from people with severe asthma
Facilitates clinical research in this population
Seeks to improve clinical practice for this condition

Patient enrolment and data collection

Patients with diagnosed severe refractory asthma and non-severe controlled asthma are systematically assessed at registration and followed up prospectively for up to 15-years. The data is submitted to a secure online database. The information collected includes non-identifying demographic details, clinical data and patient-reported outcomes.

Current modules of ASAR

Australian Benralizumab Registry (ABenRa)

The ABenRa was developed to collect and report on data from people with severe refractory eosinophilic asthma who receive benralizumab (Fasenra) treatment in Australia.

Australian Dupilumab Registry (ASADR)

The ASADR aims to examine the characteristics of people initiated on dupilumab (Dupixent) and their responses to treatment in a real-world setting in Australia.

Key publications from ASAR/SAWD

A comprehensive list of publications and further insights from ASAR can be found in the ASAR Annual Reports. Appropriate human research ethics committee/institutional review board and local research governance approvals are in place for the conduct of ASAR, ABenRa and ASADR.

If you would like to register your interest or for further information about ASAR (or the research modules), contact the TSANZ registries team:

Email: registries@thoracic.org.au

Webpage: https://thoracic.org.au/research-and-awards/australasian-severe-asthma-registry-asar/

ASAR is supported by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi.